Aktis Oncology, Inc. AKTS
16.42 USD +0.11 (+0.67%)
As ofNov 18, 2026, 12:09 PM EST
16.24 Day range 16.70
13.96 52-week range 34.19
- YTD
- -26.70%
- 1 year
- -26.70%
News
benzinga.com Aktis Oncology Q3 EPS $(0.54) Misses $(0.48) Estimate, Sales $3.905M Miss $4.016M Estimate Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.48) by 12.5 percent. This is a 97.18 percent increase over losses of…
globenewswire.com Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress Initiated the Company's third Phase 1b clinical trial, BActinium-2, broadening the evaluation of AKY-2519 to lung cancer and other B7-H3 expressing tumors Started first backfill cohorts in the…
zacks.com Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect? The mean of analysts' price targets for Aktis (AKTS) points to a 105.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts…
